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Abstract 
Diabetic patients suffer from a high rate of cardiovascular events and such risk increases with HbA1c. However, lower-
ing HbA1c does not appear to yield the same benefit on macrovascular endpoints, as observed for microvascular 
endpoints. As the number of glucose-lowering medications increases, clinicians have to consider several open ques-
tions in the management of type 2 diabetes, one of which is the cardiovascular risk profile of each regimen. Recent 
placebo-controlled cardiovascular outcome trials (CVOTs) have responded to some of these questions, but careful 
interpretation is needed. After general disappointment around CVOTs assessing safety of DPP-4 inhibitors (SAVOR, 
TECOS, EXAMINE) and the GLP-1 receptor agonist lixisenatide (ELIXA), the EMPA-REG Outcome trial and the LEADER 
trial have shown superiority of the SGLT2-I empagliflozin and the GLP-1RA liraglutide, respectively, on the 3-point 
MACE outcome (cardiovascular death, non-fatal myocardial infarction or stroke) and cardiovascular, as well as all-cause 
mortality. While available mechanistic studies largely support a cardioprotective effect of GLP-1, the ability of SGLT2 
inhibitor(s) to prevent cardiovascular death was unexpected and deserves future investigation. We herein review the 
results of completed CVOTs of glucose-lowering medications and suggest a possible treatment algorithm based on 
cardiac and renal co-morbidities to translate CVOT findings into clinical practice.
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Background
Type 2 diabetes is characterized by a heavy atheroscle-
rotic burden, inadequate compensatory remodeling and 
accelerated plaque progression, despite extensive use of 
medical therapies [1]. In diabetic patients, macrovascu-
lar and microvascular disease are tightly linked: patients 
with proliferative retinopathy have a 25-fold higher risk 
for lower limb amputation and a 2–3 fold higher risk 
for coronary heart disease (CHD) as compared to those 
without [2]. These features account for an increased car-
diovascular disease (CVD) morbidity and mortality. CVD 
may be present at HbA1c values below the diagnostic 
threshold for diabetes [3], and in patients with overt type 
2 diabetes, for every percentage point increase in HbA1c, 
the relative risk of CVD increases by about 18 % [4]. For 
these reasons, the latest ESC/EASD Guidelines on dia-
betes, pre-diabetes, and CVD emphasize the need for a 
stringent approach in patients with diabetes, underlying 
the importance of a patient-centered care [5]. In sum-
mary, in patients with type 2 diabetes, there is an excess 
risk and burden of CVD, which parallels the worsening of 
glycemic control.
Several mechanisms are though to be responsible for 
cardiovascular damage in diabetic patients, including 
hyperglycemia and oxidative stress [6], hypoglycemia 
[7], hyperinsulinemia and insulin resistance [8, 9]. These 
mechanisms can be countered by the use of different glu-
cose-lowering medications, which are therefore expected 
to reduce cardiovascular risk in patients with diabetes, in 
addition to lowering HbA1c <7.0 %, which is still consid-
ered the goal to maximise cardiovascular benefit [10, 11]. 
Nonetheless, a survey from the ESC suggests that there is 
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wide space to improve the management of patients with 
diabetes and cardiovascular disease [12].
We herein aim to briefly re-analyse the results of ran-
domized controlled trials (RCTs) reporting the effects of 
various glucose-lowering medications on cardiovascular 
outcomes in patients with type 2 diabetes. To this end, we 
run a PubMed search for RCTs with the following terms: 
“type 2 diabetes” “randomized controlled trial” “cardio-
vascular” and screened for cardiovascular outcome trials 
(CVOTs) assessing safety or efficacy of glucose-lowering 
medications.
The macrovascular paradox
While there is much evidence that the risk of CVD 
increases along with HbA1c, intervention trials aimed 
at determining whether tight glycemic control is asso-
ciated with a reduction in CVD have offered contro-
versial results (meta-analyzed in [13]). This is reflected, 
for example, by the observation that there is no cor-
relation between the glycaemic control and coronary 
vascular function in diabetic patients [14]. We call this 
the “macrovascular paradox”: i.e. the failure to reduce 
macrovascular complications to the same extent as the 
microvascular complications, despite comparable reduc-
tions in HbA1c. A number of algorithms have been 
proposed to ensure glycemic control whenever lifestyle 
measurements fail to keep HbA1c at target. The choice 
of drugs in the treatment strategy is mainly based on effi-
cacy, risk of hypoglycaemia, effect on body weight, other 
side effects and, ultimately, costs. Effect on CVD risk is 
an important item that may guide drug selection. Multi-
ple reasons have been claimed to potentially account for 
the negative findings of CVD reduction trials, includ-
ing: drug-induced hypoglycemia, weight gain, other side 
effects, wrong HbA1c target, short duration of the tri-
als. A likely explanation for the CVD paradox may rely 
on the multifactorial nature of the CVD risk in diabetes, 
as highlighted by the results of the STENO-2 study [15]. 
As a corollary of this, pharmacologic agents with effects 
exceeding the glucose lowering action may be expected 
to confer either negative or positive impacts on CVD.
Trials on cardiovascular effects of glucose lowering 
agents
Several articles have already extensively reviewed pre-
clinical and clinical findings on the cardiovascular effects 
of glucose-lowering medications [16–21]. We herein 
focus on data coming from early trials and from so-called 
cardiovascular outcome trials (CVOT) requested by reg-
ulatory agencies for marketing authorization approval 
[22].
Metformin is widely accepted as the first-choice agent 
for glucose lowering largely because of the results of the 
UKPDS sub-study showing a significant 39  % reduc-
tion in myocardial infarction (MI) in a limited number 
of overweight diabetic patients. After 10  years of the 
UKPDS post-trial monitoring, a significant reduction in 
nonfatal MI was observed in patients in the intensive arm 
(initially treated with insulin or sulfonylureas) [23]. How-
ever, metformin use has been recently questioned on the 
basis of both efficacy and outcomes [24]. In the UKPDS, 
the SU use, despite significant increase in hypoglycemia, 
was not associated to an increase in MI fatality compared 
to no SU use [25]. The action in diabetes and vascular 
disease: preterax and diamicron modified release con-
trolled evaluation (ADVANCE) trial showed that inten-
sive glycemic control based on gliclazide modified release 
reduced the incidence of combined major macro- and 
microvascular events, primarily because of a reduction in 
the incidence of new or worsening nephropathy [26]. In 
the Outcome Reduction With an initial glargine interven-
tion (ORIGIN) trial, early use of basal insulin to achieve 
normal fasting plasma glucose levels had no effect on 
CVD outcomes compared with guideline-suggested gly-
cemic control [27].
In the STOP-NIDDM trial, acarbose was initially sug-
gested to reduce cardiovascular risk in patients with 
impaired glucose tolerance [28]. Furthermore, a meta-
analysis of long term studies concluded that a similar 
effect may be present in type 2 diabetes, but the number 
of patients was very small and the conclusion of the anal-
ysis was very controversial and not reproducible [29–31].
An additional option in treatment algorithms is the 
use of thiazolidinediones. In the Prospective Pioglita-
zone Clinical Trial in Macrovascular Events (PROac-
tive), pioglitazone, a PPAR-gamma agonist, when added 
to baseline anti-hyperglycemic regimen, had no apparent 
benefit on a broad, combined, primary end point [32]. 
However, a pre-specified secondary outcome (MI, stroke, 
and cardiovascular mortality) was reduced by 16  %, in 
spite of an increase in heart failure (HF). A different tale 
is known for rosiglitazone, which has been implicated 
in an increase risk of MI [33, 34], although most recent 
analyses have casted doubts on the initial data interpre-
tation [35]. Negative CVD outcomes have been reported 
with the use of dual PPAR alpha-gamma agonists Tesagli-
tazar and Muraglitazar [36].
The lesson of the cardiovascular outcome trials
In 2008, following the withdrawal of rosiglitazone from 
the market because of potential negative impact on CVD 
outcomes [33, 34], the Food and Drug Administration 
(FDA) issued guidance on the assessment of CVD risk 
for all new drugs to treat type 2 diabetes [22]. Following 
this, a large number of patients with type 2 diabetes have 
been enrolled in CV outcome trials (CVOT, summarized 
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in Table 1). We now have the results of 6 of such trials: 
3 assessing safety of dipeptidyl peptidase (DPP) 4 inhibi-
tors [37–39], 2 testing the safety of a glucagon-like pep-
tide-1 receptor agonist (GLP1-RA) [40, 41], and 1 of an 
inhibitor of the sodium-glucose co-transporter (SGLT)-2 
[42]. All DPP4-I CVOTs met the safety primary endpoint 
of non-inferiority versus placebo with respect to 3-point 
MACE (CVD mortality, non-fatal myocardial infarction, 
and non-fatal stroke). In the Saxagliptin Assessment of 
Vascular Outcomes Recorded in Patients with Diabetes 
Mellitus (SAVOR) trial, a statistically significant increase 
in hospitalization for HF was observed in the patients 
randomized to saxagliptin, although no increase in CVD 
mortality occurred in these individuals. This was not 
observed in CVOTs assessing sitagliptin and aloglip-
tin [38, 39]. The issue of hospitalization for heart failure 
has been subsequently analyzed in several observational 
trials [43] and meta-analyes [44], most concluding for a 
neutral effect of DPP4-I on heart failure risk.
In the evaluation of lixisenatide in acute coronary syn-
dromes (ELIXA) trial, the use of lixisenatide in diabetic 
patients with a recent acute coronary syndrome showed 
neutrality on CVD outcomes with no increase in the risk 
of heart failure hospitalization [40].
Both DPP4-I and GLP-1RA have been integrated in 
treatment algorithms before the results of these trials 
were published/disclosed, mainly because of the favora-
ble efficacy-safety profile. With the question remaining 
open with respect to the increased risk of hospitalization 
for heart failure reported in SAVOR trial (not confirmed 
in any other study), overall evidence is available for safe 
use of DPP4-I across populations with different degree 
of CVD risk, including those with recent acute coronary 
syndrome [38]. Though these results have been welcome 
as reassuring, the diabetes community continues asking 
whether these treatments may, under different circum-
stances, lend to some degree of CVD protection.
EMPA‑REG Outcome trial and LEADER trial
Results of the two latest CVOTs, namely the EMPA-REG 
Outcome trial [42] and the Liraglutide effect and action 
in diabetes: Evaluation of cardiovascular outcome results 
(LEADER) trial [41] have recently stirred much enthusi-
asm. In these trials, as in SAVOR, TECOS and ELIXA, 
diabetic patients at very high CVD risk, were enrolled to 
determine the CVD safety of the SGLT2 inhibitor empa-
gliflozin and the GLP-1RA liraglutide.
In the EMPA-REG Outcome trial, the primary outcome 
was a composite of death from CV causes, nonfatal myo-
cardial infarction, and nonfatal stroke (3-point MACE). 
Two daily doses of the drug were tested: 10 and 25 mg. As 
compared to placebo, empagliflozin (pooled analyses of 
10 and 25 mg) showed non-inferiority for 3-point MACE, 
non-inferiority for 4-point MACE (including hospitaliza-
tion for unstable angina), superiority for 3-point MACE 
and not for 4-point MACE. With respect to secondary 
endpoints, patients randomized to empagliflozin had sig-
nificantly reduced risk of hospitalization for HF by 35 %, 
reduced risk CV death by 38 %, and reduced risk for all-
cause mortality by 32  %. The mechanisms responsible 
for these results are still unclear, being possibly related 
to pleiotropic effects on risk factors, to hemodynamic 
effects, and possible direct effects on the heart and vas-
culature [45, 46]. Furthermore, empagliflozin, compared 
to placebo, significantly slowed progression of kidney 
disease and loss of glomerular filtration over time in high-
risk patients of the EMPA-REG Outcome trial [47].
In the LEADER trial, the primary endpoint was the 
same as in the EMPA-REG Outcome trial [41]. In the 
primary data set and in per protocol analyses, compared 
to placebo, liraglutide significantly reduced occurrence 
of the 3-point MACE by 13  %, cardiovascular death by 
22 %, and all-cause mortality by 15 %, without significant 
effects on non-fatal MI, non-fatal stroke and hospitaliza-
tion for heart failure [41]. These findings appear to some 
extent similar to what observed in the EMPA-REG Out-
come trial, and occurred in parallel with mild reductions 
in body weight and systolic blood pressure [41].
In EMPA-REG, the early and unusual divarication 
of mortality curves deserves attention. Unlike in the 
LEADER, such a rapid effect suggests treatment has little 
effect on the atherosclerotic process pointing for an effect 
unlikely to be mediated through the modulation of glu-
cose or lipid metabolism. Similarly, the modest reduction 
of body weight, is unlikely to account for the reported 
effect. More interesting is the effect on blood pressure, 
although prior trials using blood pressure lowering drugs 
have shown a positive effect on CVD outcome to occur 
at a later time than in EMPA-REG [48]. A minor impact 
on the atherosclerotic process is also supported by the 
lack of any significant effect on nonfatal MI and stroke. 
These results suggest that the use of empagliflozin does 
not necessary protect from the CV event, rather with the 
mortality linked to the event itself.
Of note, the early separation of the mortality curves is 
paralleled by an even earlier divarication of the curves 
for hospitalization for heart failure, suggesting at least 
part of the beneficial effect of empagliflozin to be exerted 
through volume depletion: in keeping with this, a 4  % 
hematocrit increase was recorded in the empagliflozin 
treated patients [49]. Ferrannini et al. have speculated on 
the mechanisms at work suggesting that a switch to fatty 
acid utilization, concurrent with better oxygen delivery 
to the tissues, cooperates with small changes in body 
weight and blood pressure to achieve cardioprotection by 
SGLT2 inhibition [50].
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In the LEADER trial, survival curves for 3-point MACE 
and mortality separate later (since about 12–18  months 
from randomization), and there were no effect on heart 
failure. This observation suggests that liraglutide, differ-
ently from empagliflozin, may reduce the occurrence of 
cardiovascular events mainly by preventing progression 
of atherosclerosis, possibly thanks to a better control of 
risk factors and despite a mild rise in heart rate [41]. This 
view is supported by a wealth of pre-clinical and patho-
physiologic studies (reviewed in [17]).
While we wait for additional studies able to clarify 
which mechanism(s) can explain the improvement in 
CVD outcomes by empagliflozin and liraglutide, the 
clinical implications of these results need to be criti-
cally put in the perspective of current guidelines, treat-
ment algorithms, and health care economy. With respect 
to this, a number of questions need to be addressed: 1. 
Can the results obtained with empagliflozin and liraglu-
tide extended to other drugs of the same class? By now, 
of the two GLP-1RA evaluated in CVOTs, only liraglutide, 
but not lixisenatide, achieved cardioprotection. Before 
concluding for a drug-specific effect, differences in the 
patient populations and study design between ELIXA and 
LEADER trials should be taken into account (Table  1), 
whereas results of ongoing trials with other GLP-1RAs 
will help concluding on a class-effect. 2. As the proportion 
of patients with established CVD was high in the EMPA–
REG (75.6 % had CAD) and LEADER (81.3 % had CVD), 
can the results obtained be translated to other patient cat-
egories, i.e. patients without established CVD? 3. Is there 
a specific sub-population that may derive a specific benefit 
from the treatment with SGLT2-I and GLP-RA? Answer-
ing these questions will require further analysis of the 
EMPA-REG and LEADER databases as well as more spe-
cific clinical and mechanistic studies. So far, in both the 
EMPA-REG Outcome trial and the LEADER trial, there 
is a signal indicating that patients with renal impairment 
are those who benefited most from treatment with empa-
gliflozin and liraglutide, respectively, as both drugs appear 
to reduce kidney-related endpoints [41, 47]. Yet, initiat-
ing therapy with empagliflozin is still not recommended 
in patients with eGFR  <60  ml/min/1.73  m2. While this 
limitation may change in the near future, liraglutide can 
already be used in patients with stage III CKD, being not 
indicated in patients with eGFR <30 ml/min/1.73 m2.
Results of the CVOT with canagliflozin (CANVAS) 
and dapagliflozin (DECLARE) will shed further light on 
the results obtained with empagliflozin, possibly showing 
whether the beneficial effects shown in the EMPA-REG 
outcome trial can be extended to the SGLT2-inhibitor class 
and to individuals with a different CV risk profile [21].
Yet, a 22 and 38  % risk reduction of CVD mortality 
observed with liraglutide and empagliflozin, respectively, 
is too strong to be overlooked, and will likely require a 
favorable revision of the positioning of these drugs in the 
current treatment algorithm of type 2 diabetes. In order 
to do so, some features of the EMPA-REG and LEADER 
trials are worth a consideration. First of all, the results 
of the trial pertain to a well-defined diabetic population, 
i.e. patients with established prior CV events. As such, 
it cannot be generalized to the wide spectrum of clinical 
diabetes; in this context, particularly striking have been 
the superiority of the primary outcome in patients with 
an age ≥65  years, and the death for CV causes in the 
group with body mass index <30 kg/m2.
Comorbidities‑driven treatment
In patients with type 2 diabetes, especially in the elderly, 
the presence of CVD is central, with emphasis on con-
comitant heart failure and chronic kidney disease (CKD). 
In obese patients, treatment should aim at improving 
glycemic control and reducing body weight. Although 
evidence for the CV protection of metformin is rather 
limited, the drug has become quite familiar after more 
than 50 years of use, has advantageous cost effectiveness 
and a modest lowering effect on body weigh to remains 
the preferred background treatment.
If the patient has asymptomatic CVD or prior MACE 
and eGFR ≥60 ml/min/1.73 m2 and heart failure NYHA 
class I–III, metformin plus empagliflozin/liraglutide 
should be considered as these are the typical patients 
included in the EMPA-REG Outcome and LEADER 
trials, with liraglutide currently being usable in stage 
III CKD. For patients with no sign of heart failure, 
either pioglitazone (or DPP4-I) may represent a thera-
peutic option. For patients with a eGFR of 60–30  ml/
min/1.73 m2, liraglutide should be consider the preferred 
choice. Though 26 % of patients in the EMPA-REG Out-
come trial fell in this eGFR category and they benefited 
most in terms of cardiovascular protection, initiation of 
empagliflozin is currently discouraged in stage III CKD, 
and lower glycemic effect is expected. DPP4-I can be 
used even with an eGFR <30 ml/min/1.73 m2 because of 
their overall safety and efficacy, granted dose adjustment 
is made for the compounds requiring it.
If the patient has evidence of CKD without heart fail-
ure, pioglitazone can be a reasonable option as shown in 
a subanalysis of the PROactve trial [51]. Insulin and SU, if 
needed, should be used with caution because of potential 
risk of hypoglycaemia, for the latter gliclazide modified 
release may be a preferred choice because of the available 
data obtained in ADVANCE [26]. The ORIGIN trial has 
clearly demonstrated cardiovascular safety of insulin glar-
gine, and the risk of hypoglycemia with basal insulin is 
lower than during basal-bolus regimen. However, as glar-
gine and liraglutide show similar glycemic effects [52, 53], 
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the latter should be preferred for the lower hypoglycemia 
risk [54] and in view of the LEADER trial [41], except for 
eGFR <30 ml/min/1.73 m2. In general terms, use of insu-
lin has been shown to be effective even in the log run in 
patients with acute coronary syndrome in the DIGAMI 1 
trial [55, 56], though superiority of insulin over standard 
care was not confirmed the DIGAMI 2 [57].
In patients without CVD, a SGLT2-I or a GLP-1RA 
should be considered if body weight loss is required, 
whereas a DPP4-I can be considered whether when 
weight neutrality is sought. In this context, incretin-
based therapy has greater HbA1c reduction if patients 
have obesity/metabolic syndrome with a greater effect 
for GLP-1RA as compared to DPP4-I [58]. Pioglitazone 
could be considered if obesity is associated with evi-
dence for marked insulin resistance as supported by the 
co-existence of dyslipidemia, inflammatory markers, and 
subclinical CVD [59, 60].
In non-obese or mildly obese patients, the prevention 
of body weight gain may represent an important target 
along with glycemic control. In this case, a DPP4-I can 
represent a good choice due to its weight neutrality and 
the overall and CVD safety. In the case of leaner patients, 
additional treatment options may be gliclazide modified 
release and insulin. The former has been shown to sig-
nificantly decrease new or worsening nephropathy with 
relatively little risk for severe hypoglycemia [26], while 
CV safety of basal insulin in the early stage of diabetes 
is supported by the results of the ORIGIN study [27]. It 
must be mentioned that in many patients, triple (if not 
quadruple) oral or oral plus injective treatment becomes 
necessary during the course of the disease: this implies 
subsequent decisions about drug combinations. Nowa-
days choices are multiple and it should always be care-
fully considered the many aspects of clinics phenotype 
as suggested by the ADA/EASD guidelines. This makes 
the proposition of a more stringent algorithm difficult 
(Fig. 1).
Limitations
The view presented in this article is largely based on 
results from RCTs. It should be noted that, although 
such mega-trials provide the highest level of evidence, 
they have intrinsic characteristics that limit their 
Fig. 1 A treatment algorithm based on cardiac and renal co-morbidities and CVOTs. 1To be used with caution because of the risk of hypoglycemia; 
2consider dose reduction (except for linagliptin) and monitor eGFR frequently; 3preferred in the presence of marked insulin resistance; 4initiation of 
therapy currently not recommended. aUKPDS; bPROACTIVE trial; cSAVOR; dTECOS, eEXAMINE; fLEADER trial; gEMPA-REG Outcome trial; hORIGIN trial; 
kADVANCE; jELIXA; mDIGAMI 1
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generalizability and transferability to clinical practice. 
We have already mentioned that the study population 
in most CVOTs is very different from the entire popula-
tion of patients who are entitled to receive the respective 
medication. In fact, RCTs differ from clinical practice in 
several instances. For this reason, there is great interest 
in real world evidence (RWE) on glucose-lowering medi-
cations and how these fit with results from RCTs (Fig. 2). 
Data from RWE studies can complement RCTs, but they 
provide a lower level of evidence and can yield quite dif-
ferent results. This has been clearly shown for the risk 
of hospitalization for heart failure in DPP-4i treated 
patients, where meta-analyses of RCTs and observa-
tional studies [43] can reach to different conclusions [44]. 
Nonetheless, we endorse the importance of RWE in the 
evaluation of glucose-lowering medications, especially to 
explore aspects that cannot be extracted from RCTs. For 
instance, placebo-controlled RCTs may be poorly inform-
ative for clinical practice because they do not provide a 
comparative assessment of different glucose-lowering 
medications against cardiovascular outcomes, whereas 
RWE data can evaluate complex regimens against cardio-
vascular risk [61].
In addition, we would like to underline that the phar-
maco-centric view presented here ignores the impor-
tance of a healthy lifestyle and a comprehensive approach 
to prevent cardiovascular disease, as originally shown in 
the STENO-2 study [15], and confirmed by the analysis 
of treatment-dependent and -independent factors asso-
ciated with cardiovascular morbidity [62], as well as by 
the effects of a multidisciplinary risk assessment and 
management program [63]. Although the Look-AHEAD 
study found no cardiovascular benefit of an intensive life-
style intervention that promoted weight loss [64], there 
are still reasons to recommend lifestyle changes in type 
2 diabetes mellitus and obesity since early disease stages 
[65]. Finally, bariatric surgery, another non-pharmaco-
logic approach, may reduce cardiovascular risk in obese 
people with type 2 diabetes, as shown by recent meta-
analyses of observational studies [66, 67].
Conclusions
The most recent CVOTs have expanded our knowledge 
on the potential effects of glucose-lowering agents on 
CVD risk. Though most of them have proven CVD safety, 
the EMPA–REG Outcome trial and LEADER trial have 
provided evidence for significant improvement of CVD 
outcomes. While we do not yet have firm explanations 
for the mechanisms accounting for the observed benefi-
cial effect or whether any specific population may benefit 
more (for instance patients with heart failure or CKD), it 
sounds legitimate to try putting these observations in the 
Fig. 2 The interplay between data derived from CVOTs and real world evidence for assessing the cardiovascular effects of glucose-lowering agents. 
RSG rosiglitazone, CVOTs cardiovascular outcome trials, RWE real world evidence, RR risk ratio
Page 9 of 11Avogaro et al. Cardiovasc Diabetol  (2016) 15:111 
perspective of current treatment algorithms. We believe 
this exercise is needed to avoid inappropriate over-use 
of SGLT2-I and GLP-1RA, before all needed informa-
tion is gathered while ensuring they are used in keep-
ing with the available evidence. Central to our proposal 
is the presence of CVD. Patient’s phenotype, degree of 
renal function, presence of heart failure, allows for a fur-
ther patient’s population breakdown for more appropri-
ate pharmacologic treatment selection. The results of the 
EMPA-REG and LEADER trials mostly support the use 
of empagliflozin or liraglutide in patients who have estab-
lished CVD, a prior MACE, with or without stage I–III 
CKD, but we still do not know whether similar positive 
effects should be extended to the other drugs of the same 
classes.
The prevention of CVD complications and the safe 
treatment of patients who already have suffered a CVD 
event, especially in the elderly patients, remain a major 
task in treating type 2 diabetes. CVOTs and RWE data 
represent the basis for evidence-based treatment though 
we must acknowledge this is a moving target as results of 
new and ongoing trial will be released requiring a con-
stant revision of treatment algorithms.
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